Skip to content

survey the effect of alpha-lipoic acid supplementation on some biomarkers of oxidative stress and inflammation, clinical symptoms and quality of life in patients with ulcerative colitis: a clinical trial

survey the effect of alpha-lipoic acid supplementation on some biomarkers of oxidative stress and inflammation, clinical symptoms and quality of life in patients with ulcerative colitis: a clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240522061867N1
Enrollment
56
Registered
2024-05-31
Start date
2024-07-05
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis. K51

Interventions

Intervention 1: Intervention group: 600 mg of alpha lipoic acid (in the form of two 300 mg capsules made by Raha company) for 8 weeks. Intervention 2: Control group: tow placebo per day (made by Raha

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age 25 to 55 years Body mass index in the range of 18.5-27 Diagnosing ulcerative colitis according to clinical, colonoscopic, and histopathological findings by a gastroenterologist Lack of cancer, other autoimmune and inflammatory diseases Having a mild to moderate form of the disease (the severity of the disease in people is determined by a gastroenterologist based on international standards) Not taking antioxidant supplements in the last 2 months Willingness to participate in the intervention Lack of pregnancy, breastfeeding, or taking oral contraceptives in women

Exclusion criteria

Exclusion criteria: Recurrence of the disease that leads to hospitalization Unwillingness to continue participating in the intervention Changing the drug dose during the study

Design outcomes

Primary

MeasureTime frame
Interleukin 1 beta. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: ELISA kit.;Interleukin 8. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: ELISA kit.;Malondialdehyde. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: colorimetric method.;Superoxide dismutase. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: colorimetric method.;Clinical symptoms. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: partial mayo score questionnaire.;Quality of life. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: Inflammatory Bowel Disease Questionnaire.;Physical activity. Timepoint: The beginning of the study-The end of the eighth week. Method of measurement: IPAQ Physical Activity Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAva kheirizadeh

Ahvaz University of Medical Sciences

avakheirizadeh@Gmail.com+98 61 4329 3666

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026